ArticleJournal of experimental neuroscience2017
Fibroblast Growth Factor-2: A Promising Biomarker for Anxiety and Trauma Disorders.
Article in Journal of experimental neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Across Barriers: Blood-Brain and Gut Barrier Signaling in Psychiatric Disorders.Journal of neurochemistry · 2025Review
- A Prospective Cohort Study on the Effects of Repeated Acute Stress on Cortisol Awakening Response and Immune Function in Military Medical Students.Biomedicines · 2024Article
- The Molecular Basis of Resilience: A Narrative Review.Frontiers in psychiatry · 2022Review
- Salivary Biomarkers of Stress, Anxiety and Depression.Journal of clinical medicine · 2021Review
- What Can We Learn from FGF-2 Isoform-Specific Mouse Mutants? Differential Insights into FGF-2 Physiology In Vivo.International journal of molecular sciences · 2020Review
- Metabolomic Biomarkers in Anxiety Disorders.International journal of molecular sciences · 2020Review
- Inhibition of FGF Receptor-1 Suppresses Alcohol Consumption: Role of PI3 Kinase Signaling in Dorsomedial Striatum.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety and trauma disorders are a significant source of global burden. Although it is clear that there is great heterogeneity in humans' response to trauma and stress, most research on fear and anxiety has focused on the "average" animal. Increased understanding of the sources of individual differences in fear reactions may lead to more refined means of predicting who is at risk for the development of anxiety disorders so that early preventative interventions can be implemented. This commentary highlights recent cross-species work (in rats and humans) indicating that the neurotrophin fibroblast growth factor-2 (FGF2) holds promise as a potential biomarker for anxiety disorder vulnerability. Both central (hippocampal) and peripheral (serum and saliva) markers of FGF2 correlate negatively with fear expression after an aversive conditioning experience. Here, 2 broad accounts of the potential mechanism of vulnerability captured by measures of FGF2 are outlined. In particular, it is suggested that basal differences in FGF2 (across different tissue types) may provide a general index of one's regenerative capacity; alternatively, differences in FGF2 reactivity (in specific tissue types) may be indicative of one's coping capacity in response to stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.